The Interdisciplinary Stem Cell Institute's Use of Food and Drug Administration-Expanded Access Guidelines to Provide Experimental Cell Therapy to Patients With Rare Serious Diseases
Bellio, Michael A
Schulman, Ivonne H
Levi, Allan D
DiFede, Darcy L
Pujol, Marietsy V
Yavagal, Dileep R
Bates, Karen E
Green, Barth A
Anderson, Kimberly D
Guest, James D
Burks, Stephen Shelby
Santamaria, Andrea J
Dietrich, W Dalton
Hare, Joshua M
JournalFrontiers in Cell and Developmental Biology
PublisherFrontiers Media S.A.
MetadataShow full item record
AbstractThe U.S. Food and Drug Administration (FDA) provides guidance for expanded access to experimental therapies, which in turn plays an important role in the Twenty-first Century Cures Act mandate to advance cell-based therapy. In cases of incurable diseases where there is a lack of alternative treatment options, many patients seek access to cell-based therapies for the possibility of treatment responses demonstrated in clinical trials. Here, we describe the use of the FDA’s expanded access to investigational new drug (IND) to address rare and emergency conditions that include stiff-person syndrome, spinal cord injury, traumatic brain stem injury, complex congenital heart disease, ischemic stroke, and peripheral nerve injury. We have administered both allogeneic bone marrow-derived mesenchymal stem cell (MSC) and autologous Schwann cell (SC) therapy to patients upon emergency request using Single Patient Expanded Access (SPEA) INDs approved by the FDA. In this report, we present our experience with 10 completed SPEA protocols. © Copyright © 2021 Khan, Bellio, Schulman, Levi, Longsomboon, Brooks, Valasaki, DiFede, Pujol, Yavagal, Bates, Si, Kaushal, Green, Anderson, Guest, Burks, Silvera, Santamaria, Lalwani, Dietrich and Hare.
Rights/TermsCopyright © 2021 Khan, Bellio, Schulman, Levi, Longsomboon, Brooks, Valasaki, DiFede, Pujol, Yavagal, Bates, Si, Kaushal, Green, Anderson, Guest, Burks, Silvera, Santamaria, Lalwani, Dietrich and Hare.
expanded access IND
mesenchymal stem cells
single patient IND
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/16108
- Ten-Year Experience for the Center for Drug Evaluation and Research, Part 2: FDA's Role in Ensuring Patient Safety.
- Authors: Jarow JP, Lemery S, Bugin K, Lowy N
- Issue date: 2017 Mar 1
- Bone Marrow Concentrate (BMC) Therapy in Musculoskeletal Disorders: Evidence-Based Policy Position Statement of American Society of Interventional Pain Physicians (ASIPP).
- Authors: Manchikanti L, Centeno CJ, Atluri S, Albers SL, Shapiro S, Malanga GA, Abd-Elsayed A, Jerome M, Hirsch JA, Kaye AD, Aydin SM, Beall D, Buford D, Borg-Stein J, Buenaventura RM, Cabaret JA, Calodney AK, Candido KD, Cartier C, Latchaw R, Diwan S, Dodson E, Fausel Z, Fredericson M, Gharibo CG, Gupta M, Kaye AM, Knezevic NN, Kosanovic R, Lucas M, Manchikanti MV, Mason RA, Mautner K, Murala S, Navani A, Pampati V, Pastoriza S, Pasupuleti R, Philip C, Sanapati MR, Sand T, Shah RV, Soin A, Stemper I, Wargo BW, Hernigou P
- Issue date: 2020 Mar
- FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
- Authors: Rossen BR
- Issue date: 2009
- Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the "Right to Try".
- Authors: Van Norman GA
- Issue date: 2018 Apr
- Overview of FDA's Expanded Access Program for Investigational Drugs.
- Authors: Jarow JP, Lurie P, Ikenberry SC, Lemery S
- Issue date: 2017 Mar 1